Literature DB >> 17609392

Functional antibodies to the O-acetylated pneumococcal serotype 15B capsular polysaccharide have low cross-reactivities with serotype 15C.

Gowrisankar Rajam1, George M Carlone, Sandra Romero-Steiner.   

Abstract

The 23-valent pneumococcal polysaccharide (Ps) vaccine offer protection against vaccine serotypes, but its cross-protection against vaccine-related serotypes is variable. We have demonstrated that the functional antibodies to serotype 15B are specific to the O-acetylated 15B-Ps and that they have low cross-reactivity with serotype 15C. Demonstration of functionally cross-reactive antibodies to vaccine-related serotypes is important for surveillance and vaccine development.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17609392      PMCID： PMC2043308          DOI： 10.1128/CVI.00184-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  23 in total

1.  Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.

Authors:  S Romero-Steiner; D Libutti; L B Pais; J Dykes; P Anderson; J C Whitin; H L Keyserling; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

Review 2.  Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.

Authors:  J B Robbins; R Austrian; C J Lee; S C Rastogi; G Schiffman; J Henrichsen; P H Mäkelä; C V Broome; R R Facklam; R H Tiesjema
Journal:  J Infect Dis       Date:  1983-12       Impact factor: 5.226

3.  Serum samples from infants vaccinated with a pneumococcal conjugate vaccine, PncT, protect mice against invasive infection caused by Streptococcus pneumoniae serotypes 6A and 6B.

Authors:  E Saeland; H Jakobsen; G Ingolfsdottir; S T Sigurdardottir; I Jonsdottir
Journal:  J Infect Dis       Date:  2000-12-08       Impact factor: 5.226

Review 4.  Pneumococcal vaccination: current and future issues.

Authors:  A Ortqvist
Journal:  Eur Respir J       Date:  2001-07       Impact factor: 16.671

5.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

6.  Structural studies of the capsular polysaccharide from Streptococcus pneumoniae types 15B and 15C.

Authors:  P E Jansson; B Lindberg; U Lindquist; J Ljungberg
Journal:  Carbohydr Res       Date:  1987-04-15       Impact factor: 2.104

7.  Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine.

Authors:  Sheldon L Kaplan; Edward O Mason; Ellen R Wald; Gordon E Schutze; John S Bradley; Tina Q Tan; Jill A Hoffman; Laurence B Givner; Ram Yogev; William J Barson
Journal:  Pediatrics       Date:  2004-03       Impact factor: 7.124

8.  Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.

Authors:  J C Butler; R F Breiman; J F Campbell; H B Lipman; C V Broome; R R Facklam
Journal:  JAMA       Date:  1993-10-20       Impact factor: 56.272

9.  Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction.

Authors:  Robert E Gertz; M Catherine McEllistrem; David J Boxrud; Zhongya Li; Varja Sakota; Terry A Thompson; Richard R Facklam; John M Besser; Lee H Harrison; Cynthia G Whitney; Bernard Beall
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

10.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Authors:  Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245
View more
  14 in total

1.  A new pneumococcal serotype, 11E, has a variably inactivated wcjE gene.

Authors:  Juan J Calix; Moon H Nahm
Journal:  J Infect Dis       Date:  2010-07-01       Impact factor: 5.226

2.  The Pneumococcal Serotype 15C Capsule Is Partially O-Acetylated and Allows for Limited Evasion of 23-Valent Pneumococcal Polysaccharide Vaccine-Elicited Anti-Serotype 15B Antibodies.

Authors:  Brady L Spencer; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

3.  WciG O-Acetyltransferase Functionality Differentiates Pneumococcal Serotypes 35C and 42.

Authors:  K Aaron Geno; C Allen Bush; Mengnan Wang; Cheng Jin; Moon H Nahm; Jinghua Yang
Journal:  J Clin Microbiol       Date:  2017-06-28       Impact factor: 5.948

4.  Serotype-related variation in susceptibility to complement deposition and opsonophagocytosis among clinical isolates of Streptococcus pneumoniae.

Authors:  Merit Melin; Krzysztof Trzciński; Martin Antonio; Seppo Meri; Richard Adegbola; Tarja Kaijalainen; Helena Käyhty; Merja Väkeväinen
Journal:  Infect Immun       Date:  2010-09-20       Impact factor: 3.441

Review 5.  Pneumococcal Capsules and Their Types: Past, Present, and Future.

Authors:  K Aaron Geno; Gwendolyn L Gilbert; Joon Young Song; Ian C Skovsted; Keith P Klugman; Christopher Jones; Helle B Konradsen; Moon H Nahm
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

6.  Position of O-Acetylation within the Capsular Repeat Unit Impacts the Biological Properties of Pneumococcal Serotypes 33A and 33F.

Authors:  Brady L Spencer; Jamil S Saad; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

7.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

8.  Evaluation of a novel therapeutic approach to treating severe pneumococcal infection using a mouse model.

Authors:  Nikkol Melnick; Gowrisankar Rajam; George M Carlone; Jacquelyn S Sampson; Edwin W Ades
Journal:  Clin Vaccine Immunol       Date:  2009-04-22

9.  Emerging Streptococcus pneumoniae Strains Colonizing the Nasopharynx in Children After 13-valent Pneumococcal Conjugate Vaccination in Comparison to the 7-valent Era, 2006-2015.

Authors:  Ravinder Kaur; Janet R Casey; Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2016-08       Impact factor: 2.129

10.  Structure of the capsular polysaccharide of pneumococcal serotype 11A reveals a novel acetylglycerol that is the structural basis for 11A subtypes.

Authors:  Edward R Zartler; Richard J Porambo; Carrie L Anderson; Lorenzo H Chen; Jigui Yu; Moon H Nahm
Journal:  J Biol Chem       Date:  2008-12-29       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.